Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07445074 · ClinicalTrials.gov registry record · NA
AI-Based Mobile Intervention on Medication Non-Adherence and Transition
A NA study of Epilepsy and Seizure, sponsored by University of Central Florida.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT07445074: Recruiting NA study of Epilepsy and Seizure, sponsored by University of Central Florida.
NCT07445074 is a NA study of Epilepsy and Seizure that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 200 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07445074, a NA study of Epilepsy and Seizure, is actively recruiting participants, sponsored by University of Central Florida.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.
Primary Outcome
Participants will demonstrate significant improvement in medication adherence measured by Medication adherence rate (MAR) formula: The average number of missed medications. Adherence Rate (%) = (Number of prescribed ASM doses taken / Number of prescribed ASM doses scheduled) × 100.
Interventions
- OTHER Medilepsy® Chatbot AI-Enhanced
- OTHER Medilepsy® Chatbot Standard
Study Locations (1)
Florida
- University of Central Florida - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-03 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT07445074 shows while recruiting
NCT07445074 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Medilepsy® Chatbot AI-Enhanced is the first listed.
NCT07445074 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07445074 about?
NCT07445074 is a clinical study titled "AI-Based Mobile Intervention on Medication Non-Adherence and Transition". This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epile...
What is the current status of trial NCT07445074?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2026-03. Estimated completion is 2026-12.
What conditions does trial NCT07445074 study?
This clinical trial studies the following conditions: Epilepsy, Seizure.
What interventions are being tested in trial NCT07445074?
The interventions under investigation include: Medilepsy® Chatbot AI-Enhanced (OTHER), Medilepsy® Chatbot Standard (OTHER).
Who is sponsoring clinical trial NCT07445074?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07445074 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07445074's enrollment target sits among peer trials
200 31st of 160 higher than 130 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SeizEAR Safety Study
RECRUITING · NA
-
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
RECRUITING · NA
-
Subcortical Arousal in Perceptual Awareness
RECRUITING · NA
-
Prediction of Anxiety and Memory State
RECRUITING · NA
-
Implementation and Cost Evaluation of Project UPLIFT
RECRUITING · NA
-
Amygdala Memory Enhancement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia